INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo HE ollimoino oimIE (10) International Publication Number WO 2018/185232 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/058752 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,973 05 April 2017 (05.04.2017) US (71) Applicant: SYMPHOGEN A/S [DK/DK]; Pederstrupvej 93, 2750 Ballerup (DK). (72) Inventors: LINDSTED, Trine; Hyldevwnget 13, 3520 Farum (DK). GRANDAL, Michael Monrad; Solbrinken 26a, 2750 Ballerup (DK). MELANDER, Eva Maria Carlsen; Ostra Hyllievagen 111, 216 23 Malmo (SE). FROHLICH, Camilla; Nojsomhedsvej 13, 2. th, 2100 Kobenhavn 0 (DK). PEDERSEN, Mikkel Wandahl; Forelvej 17, 3450 Alleroed (DK). KRAGH, Michael; Lwssoesgade 1A, 5. Tv., 2200 Copenhagen N (DK). LANTTO, Johan; Bryggaregaten 4, 227 36 Lund (SE). GAD, Monika; Gravenstensvej 8, 3450 Allerod (DK). HO- RAK, Ivan David; Rundholtsvej 26, 2300 Copenhagen S (DK). (74) Agent: POHLMAN, Sandra; TheatinerstraBe 16, 80333 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) ot CO (54) Title: COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3 1-1 0 (57) : This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies \' specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in 0 the therapies. The therapies are useful in treating diseases such as cancers.
COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3